Expanded Access for Treatment With Imetelstat
- Conditions
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Geron Corporation
- Registration Number
- NCT05937568
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 41
- Registration Number
- NCT05371964
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Texas Oncology, Tyler, Texas, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, Florida, United States
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-10-06
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 320
- Registration Number
- NCT04576156
- Locations
- 🇺🇸
Memorial Care, Long Beach, California, United States
🇺🇸UCLA David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸University of California-San Diego/Moores UCSD Cancer Center, La Jolla, California, United States
Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 289
- Registration Number
- NCT02598661
- Locations
- 🇺🇸
Simmons Comprehensive Cancer Center, Dallas, Texas, United States
🇺🇸Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, United States
🇧🇪UZ Leuven - Campus Gasthuisberg, Leuven, Belgium
Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 107
- Registration Number
- NCT02426086
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 80
- Registration Number
- NCT01731951
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 166
- Registration Number
- NCT01256762
- Locations
- 🇺🇸
Clearview Cancer Center, Huntsville, Alabama, United States
🇺🇸Medical Oncology Hematology, Waterbury, Connecticut, United States
🇺🇸Mid Illinois Hematology & Oncology, Normal, Illinois, United States
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT01243073
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸MDACC - Orlando, Orlando, Florida, United States
Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 13
- Registration Number
- NCT01242930
- Locations
- 🇺🇸
University of Maryland Medical Center - M & S Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Sidney Kimmel Cancer Center Johns Hopkins Hospital, Baltimore, Maryland, United States
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 116
- Registration Number
- NCT01137968
- Locations
- 🇺🇸
Integrated Community Oncology Network, Jacksonville, Florida, United States
🇺🇸Cancer Center of Kansas, Wichita, Kansas, United States
🇺🇸Ingalls Memorial Hospital, Harvey, Illinois, United States